MRX-2843 for Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, certain medications like systemic antineoplastic therapy, calcineurin inhibitors, and some anticoagulants are not allowed close to the start of the study. It's best to discuss your specific medications with the study team.
Who Is on the Research Team?
William G. Blum
Principal Investigator
Emory University
Thomas B. Alexander
Principal Investigator
UNC Lineberger Comprehensive Cancer Center, Children's
Joshua Zeidner, MD
Principal Investigator
UNC Lineberger Comprehensive Cancer Center
Melinda Pauley, MD
Principal Investigator
Emory University, Children's Healthcare of Atlanta
Are You a Good Fit for This Trial?
This trial is for adolescents and adults at least 12 years old with relapsed/refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or mixed phenotype acute leukemia (MPAL). Participants must weigh over 40 Kg, have specific blood test results within certain limits, be able to swallow pills, and not be pregnant. They should also agree to use double barrier contraception methods.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts
Dose Expansion
A dose expansion arm to further evaluate patients at the RP2D
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MRX-2843
Find a Clinic Near You
Who Is Running the Clinical Trial?
Meryx, Inc.
Lead Sponsor